Codex DNA Inc (DNAY) Stock
DNAY is no longer traded. Codex DNA was delisted from the Nasdaq in March 2023.
Prices on this page are historical; the last trade was March 7, 2023 at $2.00.
Codex DNA stock price history
DNAY final trading statistics
- Final close
- $2.00
- Final trading day
- Mar 7, 2023
- Market cap at delisting
- $59.04M
- Shares outstanding
- 29.52M
- Final 52-week range
- $1.08 – $11.02
- Avg. volume (final 3 mo.)
- 59,936
- All-time high (split-adj.)
- $396.00 · Jun 2021
- All-time low (split-adj.)
- $20.16 · Dec 2022
- Return since IPO
- -80.0%
- Beta
- —
- Book value / share
- $1.81
- Price / book
- 1.11
Codex DNA annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $11.04M | -$39.0M | -$2.17 |
| FY2020 | $6.58M | -$18.0M | -$0.48 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Codex DNA Inc
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Codex DNA stock FAQ
What happened to Codex DNA stock?
Codex DNA stock was delisted from the Nasdaq. Its final close was $2.00 on March 7, 2023.
Is DNAY stock still trading?
No. DNAY was delisted from the Nasdaq in March 2023 and no longer trades on a U.S. exchange.
What was the last price of DNAY stock?
DNAY closed at $2.00 on its final trading day, March 7, 2023, for a market value of about $59.04M.
What were Codex DNA's revenue and earnings in its last full fiscal year?
Codex DNA reported revenue of $11.04M and net income of -$39.0M in fiscal 2021, its last full year as a public company.
When did Codex DNA go public?
Codex DNA Inc stock began trading on June 18, 2021.